Engineering of siRNA molecules to silence SphK1 mRNA for therapeutic intervention in triple-negative breast cancer: An In Silico and In Vitro Analysis
{{output}}
Triple-negative breast cancer (TNBC) is an aggressive and therapeutically challenging subtype of breast cancer lacking estrogen, progesterone, and HER2 receptors. Sphingosine kinase 1 (SphK1), a key enzyme in the sphingosine-1-phosphate (S1P) signaling pathway... ...
